BioSig Technologies Inc. (NASDAQ: BSGM) stock declined by 6.31% at the last close whereas the BSGM stock-price gains by 4.4% in the after-hours trading session. BioSig Technologies is a medical technology business that sells a biomedical signal processing platform that improves signal quality and reveals the entire spectrum of ECG and intra-cardiac signals.
What is happening?
Physicians have completed 1000 patient cases using BioSig Technologies’ technology across nine installation sites, according to BioSig Technologies. The PURE EP(tm) System, a non-invasive computerized technology developed by BioSig, seeks to improve electrophysiology procedure efficiency and efficacy. In all cardiac ablations that cure irregular heartbeats or arrhythmias, the system offers crucial diagnostic signals with great clinical value.
Previously, BSGM raised the patient case target from 1000 to at least 1500 operations by the end of 2021, after completing 425 treatments in 2020. Patient cases are now being conducted by BSGM at nine medical sites around the country. With over 600 patient cases completed to far, the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX, Mayo Clinic Florida Campus, BSGM’s first commercial clients, and the University of Pennsylvania are among the most notable technology users.
BSGM is in the midst of a planned commercial launch, with a focus on increasing its clinical footprint in the Northeast, Texas, and Florida, the three regions with the country’s largest electrophysiology programs. Mr. Walt Quinn was recently appointed to manage regional sales in Florida by BSGM, which has lately increased its commercial staff. Mr. Quinn has over 25 years of experience selling medical devices and capital equipment for some of the industry’s best firms, including Ethicon (a Johnson&Johnson subsidiary), Medtronic, Topera (an Abbott company), and CardioFocus.
On July 28-31, 2021, at the Boston Event and Exhibition Center in Boston, MA, BSGM will be presenting at the annual Heart Rhythm 2021 convention. BioSig’s senior leadership, clinical, commercial, and engineering teams will give a series of talks that will highlight the most recent clinical data and showcase the PURE EP(tm) System’s newest software features.